Longeveron (LGVN) Change in Acquisitions & Divestments (2023 - 2024)
Longeveron (LGVN) posted quarterly Change in Acquisitions & Divestments of $2000.0 for Q3 2024, down 99.95% year-over-year from $3.9 million in Q4 2023, and down 99.31% quarter-over-quarter from $289000.0 in Q2 2024.
Longeveron (LGVN) Change in Acquisitions & Divestments (2023 - 2024) Analysis & Trends
Longeveron's Change in Acquisitions & Divestments history runs 2 years deep, the most recent figure standing at $2000.0 for Q3 2024.
- In Q3 2024, Change in Acquisitions & Divestments fell 99.95% year-over-year to $2000.0; the TTM figure through Dec 2024 stood at $352000.0 (down 96.04% YoY), while the FY2024 annual figure was $352000.0, down 96.04% from the prior year.
- Change in Acquisitions & Divestments for Q3 2024 stood at $2000.0, down from $289000.0 in the prior quarter.
- The five-year high for Change in Acquisitions & Divestments was $3.9 million in Q3 2023, with the low at $2000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 2,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 289,000.00 |
| Jun 30, 2024 | 289,000.00 |
| Mar 31, 2024 | 61,000.00 |
| Mar 31, 2024 | 61,000.00 |
| Dec 31, 2023 | 1.82 Mn |
| Dec 31, 2023 | 1.82 Mn |
| Sep 30, 2023 | 3.94 Mn |
| Sep 30, 2023 | 3.94 Mn |
| Jun 30, 2023 | 2.66 Mn |
| Jun 30, 2023 | 2.66 Mn |
| Mar 31, 2023 | 461,000.00 |
| Mar 31, 2023 | 461,000.00 |